Future of Aardvark’s Prader-Willi drug in doubt as FDA slaps full hold on program

Aardvark Therapeutics had previously voluntarily suspended studies of ARD-101—and a related asset called ARD-201—after detecting anomalous echocardiographic readings in healthy volunteers that could indicate reduced heart efficiency.